Scott Feitell, DO
Advanced Heart Failure and Transplant Cardiology · Rochester, NYNPI 1770815540
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $320,672 of the $422,340 with a category attached, or 75.9%. It is spread thinly across 38 manufacturers, the largest accounting for just 16.0%. Among advanced heart failure and transplant cardiology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 943 payments — averaging $447.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$68K
- Pfizer$60K
- Actelion Pharmaceuticals US, Inc.$47K
- Alnylam Pharmaceuticals Inc.$41K
- Novartis$40K
- Lexicon Pharmaceuticals, Inc.$33K
- plus $133K from 32 others
Across 21 payments — averaging $2928.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$33K
- Abbott$28K
- Novartis$395
What the payments were for
- Consulting fees$57,48514%
- Speaking & faculty fees$320,67276%
- Travel & lodging$24,8326%
- Food & beverage$19,1135%
- Education$2380%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYNDAQEL$54,498
- ENTRESTO$39,150
- AMVUTTRA$37,959
- OPSUMIT$37,702
- UPTRAVI$36,620
- Inpefa$32,740
- FARXIGA$31,974
- FUROSCIX$30,975
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$22,495
- Veltassa$20,740
- OPTIMIZER$20,230
- MitraClip$15,881
- Attruby$14,938
- HeartMate 3 Left Ventricular Assist Device$10,019
- HeartMate 3 Left Ventricular Dev$6,588
- VYNDAMAX$5,470
- TEGSEDI$5,460
- CardioMEMS HF System$4,785
- ReDS system$3,718
- ReDS$3,000
How this compares
$422,340 in reported general payments places this provider in the 95th percentile of 106 advanced heart failure and transplant cardiology providers in New York.
See all advanced heart failure and transplant cardiology providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tyvaso DpiTreprostinil | 25 | $584,719 |
| LetairisAmbrisentan | 12 | $151,873 |
| EntrestoSacubitril/Valsartan | 90 | $113,573 |
| JardianceEmpagliflozin | 61 | $82,512 |
| EliquisApixaban | 28 | $33,987 |
| FarxigaDapagliflozin Propanediol | 16 | $25,704 |
| OzempicSemaglutide | 23 | $24,735 |
| MounjaroTirzepatide | 13 | $13,451 |
| Metoprolol Succinate | 85 | $1,457 |
| Midodrine Hcl | 12 | $1,339 |
| Digoxin | 40 | $1,237 |
| Torsemide | 64 | $1,002 |
| Spironolactone | 135 | $909 |
| Ezetimibe | 35 | $430 |
| Carvedilol | 42 | $429 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $40,187 | $113,57390 claims |
| Boehringer IngelheimJardiance | $251 | $82,51261 claims |
| PfizerEliquis | $60,209 | $33,98728 claims |
| AstraZenecaFarxiga | $32,973 | $25,70416 claims |
| Novo NordiskOzempic | $210 | $24,73523 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 106 advanced heart failure and transplant cardiology providers in New York.
Other advanced heart failure and transplant cardiology in Rochester
- Johanna ContrerasNew York$534K
- Sean PinneyNew York$305K
- Mathew MaurerNew York$249K
- Gregg LanierHawthorne$239K
- Michelle BloomMineola$166K
- Norbert MoskovitsBrooklyn$159K
- Stephen PanValhalla$159K
- Dor LotanNew York$158K
- Nir UrielNew York$125K
- Gabriel SayerNew York$95K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.